Key facts
- It has raised $132.3M across 2 recorded rounds; the latest was Early Stage VC (Series B) ($132.3M) in May 2022.
- 1 institutional filer reports fund marks on SalioGen Therapeutics across 2 filings.
- SalioGen Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Apr 2022 ($132.2M sold to 24 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for SalioGen Therapeutics
Create free account
No card required
Funding rounds
2 roundsMay 2022Early Stage VC (Series B)$132.3M▮
About SalioGen Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
SalioGen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in SalioGen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Aug 20251 SEC-registered fund reported 2 fair-value marks on SalioGen Therapeutics between May 2025 and Aug 2025. Filer-level marks and implied $/share are available to Pro members.